The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid

Ramin Sadeghi, Seyed Rasoul Zakavi, Mohammad Naser Forghani, Kamran Aryana, Vahid Reza Dabbagh Kakhki, Narjes Khatoon Ayati, Fatemeh Homaee Shandiz, Mohammad Reza Ghavamnasiri, Mohammed Keshtgar
2010 Nuclear Medicine Review  
To study the value of periareolar intra-dermal injection of Tc-99m sestamibi (MIBI) for sentinel node mapping in breast carcinoma. Fifty patients with early-stage breast cancer were included in our study. 17.5 MBq Tc-99m-MIBI was injected intradermally to 25 patients and the remainders were injected with the same dose of Tc-99m-antimony sulphide colloid. Anterior and lateral static images were taken at 2 minutes. If sentinel lymph node was not detected, delayed imaging by up to 180 minutes was
more » ... to 180 minutes was carried out. The patients were operated on 2-4 hours post-injection. Sentinel lymph node biopsy was performed by the aid of gamma probe and blue dye during surgery. In the Tc-99m-MIBI group, 23 patients had lymph nodes on scintigraphy images, and sentinel nodes were detected during surgery in all 23 patients. In the Tc-99m-antimony sulphide colloid group, 24 patients had lymph nodes on scintigraphy images, and sentinel nodes were identified during surgery in 24 patients. We concluded that 99mTc-MIBI is a suitable radiopharmaceutical for sentinel node detection.
pmid:21154308 fatcat:qs2gff5gl5cnlfq4b7piuzwvqq